Austria

Aelian Biotechnology was founded in Vienna in Feb 2018 by experienced life science entrepreneurs. Aelian combines CRISPR screening with single-cell transcriptional read-out, leveraging two of the most powerful functional genomics technologies to enable drug target identification and validation as well as disease modeling.

Presenter: Thomas Moser, CEO, Aelian Biotechnology